Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.10 +1.58%

+$0.15 today

Market cap
$912.78M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 1.57M

Average 0.46M

IMTX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Immatics N.V.NASDAQ: IMTX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of €14.51M rose 20.3% year over year, ahead of the +14.4% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 6.2% from the prior quarter. Over 3 fiscal years it compounded at +12.3% a year.

Context

  • Selling, general & admin amounted to 106.0% of revenue in FY2025, up 76.2 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of €23.47M (-54.1%) for the fiscal year ending Dec 2026, a slowdown from the +10.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
€14.51M+6.2% QoQ
Last fiscal yearDec 2025
€51.18M+10.2% YoY
LTMMar 2026
€53.63M+14.4% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.3%-39.5%-59.8 pp
1 year+10.2%-54.1%-64.3 pp
3-year CAGR+12.3%+14.2%+1.8 pp
5-year CAGR+41.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

EUR · from the income statement

Latest · FY2025
51.18M EUR
Year-over-year change
+10.2%
4-year CAGR
+10.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How IMTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +14.4% is the 3rd highest of 11, against a peer median of -2.2%.
  • Selling, general & admin amounts to 143.8% of revenue for IMTX, versus a peer median of 67.6%.
IMTX Competitors
Selling, General & Admin for IMTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€788.8M EUR+45.9%+8.9%29.8%
LEGNLegend Biotech CorporationLTM Sep 2026$357.49M USD+10.5%+25.2%26.3%
IMCRImmunocore Holdings plcLTM Mar 2026$151.41M USD-3.4%—39.2%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$55.88M USD-11.2%-10.5%—
IMTXImmatics N.V.LTM Mar 2026€53.63M EUR+14.4%+12.3%143.8%
JANXJanux Therapeutics, Inc.LTM Mar 2026$42.56M USD-1.1%+23.3%196.9%
LYELLyell Immunopharma, Inc.LTM Mar 2026$40.64M USD-22.7%-27.3%131109.7%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$30.56M USD-0.6%+16.3%334.5%
DTILPrecision BioSciences, Inc.LTM Mar 2026$30.49M USD-13.9%-7.9%67.6%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$17.8M USD-55.8%-27.2%76.9%
CLLSCellectis S.A.LTM Mar 2026$9.18M USD+20.3%-1.1%13.5%
Peer median (excluding IMTX) —-2.2%-1.1%67.6%

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.76M172.83M54M155.84M48.27M
Cost of Revenue87.57M106.78M118.66M00
Gross Profit(52.81M)66.05M(64.67M)155.84M48.27M
Gross Margin-151.9%38.2%-119.8%100.0%100.0%
Research & Development87.57M106.78M118.66M148.08M183.83M
Selling, General & Admin33.81M36.12M38.2M46.45M51.18M
Operating Expenses121.05M142.88M155.72M194.45M230.28M
Depreciation & Amortization5.47M6.84M7.23M12.23M12.4M
EBITDA(87.3M)50.04M(88.93M)34.46M(185.09M)
EBITDA Margin-251.1%29.0%-164.7%22.1%-383.5%
Operating Income(86.29M)29.95M(101.73M)(38.62M)(182.02M)
Operating Margin-248.2%17.3%-188.4%-24.8%-377.1%
Interest Income133K2.48M13.85M25M17.18M
Interest Expense566K1.04M831K886K946K
Other Income / Expenses(7.04M)12.08M4.73M59.96M(16.42M)
Income Before Tax(93.34M)42.04M(96.99M)21.35M(198.44M)
Pre-Tax Margin-268.5%24.3%-179.6%13.7%-411.1%
Income Tax Expense04.55M06.13M(1.99M)
Net Income(95.06M)37.51M(96.99M)15.22M(196.45M)
Net Margin-273.5%21.7%-179.6%9.8%-407.0%
EPS (Basic)(1.51)0.55(1.20)0.14(1.54)
EPS (Diluted)(1.51)0.54(1.20)0.14(1.54)
Weighted Avg Shares62.91M67.22M80.55M108.7M122.35M
Weighted Avg Shares (Diluted)62.91M68.82M80.55M106.8M122.35M

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.